{"id":116,"date":"2018-02-02T09:22:17","date_gmt":"2018-02-02T08:22:17","guid":{"rendered":"http:\/\/felzmann-immunomed.eu\/?page_id=116"},"modified":"2018-04-26T07:56:44","modified_gmt":"2018-04-26T05:56:44","slug":"vita","status":"publish","type":"page","link":"https:\/\/felzmann-immunomed.eu\/en\/resources\/vita\/","title":{"rendered":"Curriculum vitae"},"content":{"rendered":"<h1><a href=\"https:\/\/felzmann-immunomed.eu\/alive\/wp-code\/uploads\/2018\/02\/Executive.jpg\"><img loading=\"lazy\" class=\"wp-image-5463 alignright\" src=\"https:\/\/felzmann-immunomed.eu\/alive\/wp-code\/uploads\/2018\/02\/Executive.jpg\" alt=\"\" width=\"500\" height=\"332\" srcset=\"https:\/\/felzmann-immunomed.eu\/alive\/wp-code\/uploads\/2018\/02\/Executive.jpg 4288w, https:\/\/felzmann-immunomed.eu\/alive\/wp-code\/uploads\/2018\/02\/Executive-300x199.jpg 300w, https:\/\/felzmann-immunomed.eu\/alive\/wp-code\/uploads\/2018\/02\/Executive-768x510.jpg 768w, https:\/\/felzmann-immunomed.eu\/alive\/wp-code\/uploads\/2018\/02\/Executive-1024x680.jpg 1024w, https:\/\/felzmann-immunomed.eu\/alive\/wp-code\/uploads\/2018\/02\/Executive-570x380.jpg 570w, https:\/\/felzmann-immunomed.eu\/alive\/wp-code\/uploads\/2018\/02\/Executive-285x190.jpg 285w\" sizes=\"(max-width: 500px) 100vw, 500px\" \/><\/a><\/h1>\n<h1>Work experience<\/h1>\n<h3>Since 2018<\/h3>\n<ul>\n<li>Clinical consultation immunology &amp; immuno-oncology<\/li>\n<li>Physician at the blood transfusion service of the Red Cross<\/li>\n<\/ul>\n<h3>Since 2016<\/h3>\n<ul>\n<li>Freelance work<\/li>\n<li>Consulting<\/li>\n<li>Seminars &amp; trainings in immuno-oncology<\/li>\n<li>Teaching at universities<\/li>\n<li>Popular science lectures<\/li>\n<li>Articles in journals, newspapers, social media<\/li>\n<\/ul>\n<h3>2003-2016<\/h3>\n<ul>\n<li>Founder CEO \/ CSO \/ CMO at Activartis<\/li>\n<li>Medical director, qualified person<\/li>\n<li>Biotech entrepreneur with extensive leadership experience in research &amp; development<\/li>\n<li>Translational research from the laboratory into clinical pilot studies and randomized efficacy trials<\/li>\n<li>Business license for manufacturing &amp; trade in pharmaceuticals<\/li>\n<li>Successful cooperation with national and international competent authorities<\/li>\n<li>Pharmaco-economics, cost-effectiveness, reimbursement, negotiations with health technology assessment agencies, e.g. NICE<\/li>\n<li>Up to 18 employees, 5 direct reports<\/li>\n<li>Budget responsibility up to \u20ac 2.5 million annually<\/li>\n<\/ul>\n<h3>1995-2014<\/h3>\n<ul>\n<li>Group leader tumor immunology at the St. Anna Children&#8217;s Cancer Research Institute<\/li>\n<li>Basic, preclinical, and clinical research &amp; development in immuno-oncology<\/li>\n<li>Dozens of publications in journals (see my <a href=\"https:\/\/felzmann-immunomed.eu\/en\/resources\/bibliographie\/\">bibliography<\/a>)<\/li>\n<li>Up to 8 employees, 3 direct reports<\/li>\n<li>Budget responsibility up to several hundred thousand \u20ac annually<\/li>\n<\/ul>\n<h3>1995-1998<\/h3>\n<ul>\n<li>Clinical training in pediatric oncology, St. Anna Children&#8217;s Hospital, Vienna, AT<\/li>\n<li>Specialization in immunology &amp; immuno-oncology<\/li>\n<\/ul>\n<h3>1992-1995<\/h3>\n<ul>\n<li>Postdoctoral research in immuno-oncology, cancer vaccines, Clinical Gene Therapy Branch; NIH, Bethesda, MD, USA<\/li>\n<li>Development of methods for human gene transfer in T lymphocytes and tumor cells<\/li>\n<\/ul>\n<h3>1991-1992<\/h3>\n<ul>\n<li>Clinical Training in Internal Medicine &amp; Medical Oncology, Wilhelminenspital<\/li>\n<\/ul>\n<h3>1989-1992<\/h3>\n<ul>\n<li>Research Fellow, Institute of Immunology; Medical University of Vienna, AT<\/li>\n<li>Characterization of lymphatic and myeloid leukocytes in autoimmune diseases<\/li>\n<li>Immuno-diagnostic procedures and predictive biomarkers in immuno-hematology<\/li>\n<\/ul>\n<h3>1988-1991<\/h3>\n<ul>\n<li>Doctor at the blood transfusion service of the Red Cross<\/li>\n<li>Weekend job to fund unpaid research at the Institute of Immunology<\/li>\n<\/ul>\n<h3>Since 1990<\/h3>\n<ul>\n<li>Teaching and mentoring students throughout my career<\/li>\n<li>Supervision of bachelor, master &amp; PhD students<\/li>\n<li>Lectures for undergraduate, graduate, and postdoctoral scientists<\/li>\n<li>Educational articles, books on immunology &amp; immuno-oncology for non-professionals<\/li>\n<li>Science communication, public lectures<\/li>\n<\/ul>\n<h1>Training, trainings, graduations<\/h1>\n<ul>\n<li>Pharmaceutical Quality Management, University of Vienna, AT; Graduation as Qualified Person, November 23, 2009<\/li>\n<li>Associate Professor for Immunology (Venia Docendi); Medical University of Vienna, Vienna, AT; July 9, 2007<\/li>\n<li>Executive MBA, Danube University Krems; Graduation eMBA; November 25, 2005<\/li>\n<li>Specialist in Immunology; Austrian Medical Association; December 15, 1998<\/li>\n<li>Training in pediatric hematology \/ oncology; St. Anna Children&#8217;s Hospital, AT,\u00a01995-2000<\/li>\n<li>Internal Medicine &amp; Hematology \/ Oncology; Wilhelminenspital, Vienna, AT,\u00a01990-1992<\/li>\n<li>Training in group psychotherapy and group dynamics; \u00d6AGG, Vienna, AT,\u00a01986-1989<\/li>\n<li>Medical School, University Wien, AT; Graduation Dr.med.univ; December 11, 1987<\/li>\n<li>Higher Federal Institute for Biochemistry, Teaching and Research; Vienna, AT; Matura; 3 June 1980<\/li>\n<\/ul>\n<h1>International patent families<\/h1>\n<ul>\n<li>Immune checkpoint inhibitors, EP 15156752.6 and others,\u00a02015<\/li>\n<li>Targeted cancer immunotherapy, EP 13161965.2 and others,\u00a02014<\/li>\n<li>Immune modulating dendritic cells, EP 07450233.7 and others,\u00a02007<\/li>\n<li>Methods and means for diagnosis and treatment of leukemia, A 2051\/2005,\u00a02005<\/li>\n<li>Use of dendritic cells expressing interleukin-12, WO2004024900A1 and others,\u00a02002<\/li>\n<\/ul>\n<h4>These patent families make about 100 individual patents, applied for or granted<\/h4>\n<h1>Financing<\/h1>\n<h4>15 M \u20ac from private and corporate investors (2003-2016)<\/h4>\n<h1>Research funding, competitive grants<\/h1>\n<ul>\n<li>Immune checkpoint inhibitors, Vienna Business Agency,\u00a02016-2018<\/li>\n<li>Prognostic biomarker, Austrian Research Promotion Agency,\u00a02014-2015<\/li>\n<li>Bioinformatics modeling of immune cell \/ tumor cell interactions, EU FP7,\u00a02012-2016<\/li>\n<li>Use of nano-particles in immuno-oncology, Austrian Research Promotion Agency,\u00a02013-2014<\/li>\n<li>Blocking DC-mediated immunosuppression, Austrian Research Promotion Agency,\u00a02005-2007<\/li>\n<li>Development of DC cancer vaccines, Vienna Business Agency,\u00a02004-2009<\/li>\n<li>Comparative evaluation of DC cancer vaccines, EU FP7,\u00a02003-2005<\/li>\n<li>Interleukin-12 secreting DCs in mice &amp; men,\u00a0 Austrian Research Promotion Agency,\u00a02001-2005<\/li>\n<li>Cancer immunotherapy, Austrian National Bank,\u00a02000-2001<\/li>\n<li>Methods for producing DCs, Vienna Business Agency,\u00a01999-2000<\/li>\n<\/ul>\n<h4>A total of 7.5 M \u20ac in research funding from Stadtgemeinde Wien, Republic of Austria, &amp; from the EU<\/h4>\n<h1>Scholarships<\/h1>\n<ul>\n<li>Trend Scholarship for Executive MBA, Donau University Krems, AT,\u00a02003-2005<\/li>\n<li>Fogarty Fellowship, NIH, Bethesda, MD, USA,\u00a01994-1995<\/li>\n<li>Max Kade Fellowship, Austrian Academy of Sciences, AT,\u00a01992-1993<\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>Work experience Since 2018 Clinical consultation immunology &amp; immuno-oncology Physician at the blood transfusion service of the Red Cross Since 2016 Freelance work Consulting Seminars &amp; trainings in immuno-oncology Teaching at universities Popular science lectures Articles in journals, newspapers, social media 2003-2016 Founder CEO \/ CSO \/ CMO at Activartis Medical director, qualified person Biotech&hellip;<\/p>\n<p class=\"more-link\"><a href=\"https:\/\/felzmann-immunomed.eu\/en\/resources\/vita\/\" class=\"themebutton\">Read More<\/a><\/p>\n","protected":false},"author":7656790,"featured_media":0,"parent":114,"menu_order":11,"comment_status":"closed","ping_status":"closed","template":"","meta":[],"_links":{"self":[{"href":"https:\/\/felzmann-immunomed.eu\/en\/wp-json\/wp\/v2\/pages\/116\/"}],"collection":[{"href":"https:\/\/felzmann-immunomed.eu\/en\/wp-json\/wp\/v2\/pages\/"}],"about":[{"href":"https:\/\/felzmann-immunomed.eu\/en\/wp-json\/wp\/v2\/types\/page\/"}],"author":[{"embeddable":true,"href":"https:\/\/felzmann-immunomed.eu\/en\/wp-json\/wp\/v2\/users\/7656790\/"}],"replies":[{"embeddable":true,"href":"https:\/\/felzmann-immunomed.eu\/en\/wp-json\/wp\/v2\/comments\/?post=116"}],"version-history":[{"count":10,"href":"https:\/\/felzmann-immunomed.eu\/en\/wp-json\/wp\/v2\/pages\/116\/revisions\/"}],"predecessor-version":[{"id":6091,"href":"https:\/\/felzmann-immunomed.eu\/en\/wp-json\/wp\/v2\/pages\/116\/revisions\/6091\/"}],"up":[{"embeddable":true,"href":"https:\/\/felzmann-immunomed.eu\/en\/wp-json\/wp\/v2\/pages\/114\/"}],"wp:attachment":[{"href":"https:\/\/felzmann-immunomed.eu\/en\/wp-json\/wp\/v2\/media\/?parent=116"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}